{
    "Trade/Device Name(s)": [
        "EliA\u2122 PR3s Immunoassay",
        "EliA\u2122 MPOs Immunoassay",
        "EliA\u2122 GBM Immunoassay",
        "EliA\u2122 ANCA/GBM Positive Control 100",
        "EliA\u2122 ANCA/GBM Positive Control 250"
    ],
    "Submitter Information": "Phadia US, Inc.",
    "510(k) Number": "K140225",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MOB",
        "MVJ",
        "JJY"
    ],
    "Summary Letter Date": "September 19, 2014",
    "Summary Letter Received Date": "September 24, 2014",
    "Submission Date": "October 24, 2014",
    "Regulation Number(s)": [
        "21CFR866.5660",
        "21CFR862.1660"
    ],
    "Regulation Name(s)": [
        "Multiple autoantibodies immunological test system"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "IgG antibodies to proteinase 3 (PR3)",
        "IgG antibodies to myeloperoxidase (MPO)",
        "IgG antibodies to alpha3 chain of collagen IV (GBM)",
        "ANCA/GBM antibodies"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Heparin tube",
        "EDTA tube",
        "Citrate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Phadia 100",
        "Phadia 250"
    ],
    "Method(s)/Technology(ies)": [
        "Fluorescence Immunoassay",
        "EliA IgG method"
    ],
    "Methodologies": [
        "Immunoassay",
        "Enzyme immunoassay (ELISA)",
        "Fluorescence detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Positive Control",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for EliA PR3s, MPOs, GBM immunoassays and positive controls for detection of autoantibodies using fluorescence immunoassay on Phadia analyzers.",
    "Indications for Use Summary": "EliA PR3s, MPOs, and GBM immunoassays are for the in vitro semi-quantitative measurement of specific IgG autoantibodies in human serum and plasma to aid in the diagnosis of Granulomatosis with Polyangiitis, Microscopic Polyangiitis, and Goodpasture syndrome respectively; positive controls monitor assay performance on Phadia 100/250 instruments.",
    "fda_folder": "Immunology"
}